Tsubota Laboratory Lab Reaches Milestone in Near-Sightedness Device Trial

TOKYO, Jul 22 (Pulse News Wire) – Tsubota Laboratory Incorporated (4890.T) announced the submission of the final clinical study report (CSR) for its near-sightedness prevention device TLG-001, achieving a milestone and securing a milestone payment. The trial results showed a trend indicating reduced myopia progression among children with less exposure to violet light, supporting the company's hypothesis linking outdoor activity levels and myopia development.

The milestone achievement will be reflected in the sales revenue for the second quarter of fiscal 2027. The TLG-001 trial involved analyzing data from children who spent varying amounts of time outdoors, finding a significant trend toward reduced myopia progression in those with lower exposure to violet light. While the primary endpoint was not met across all cases, the findings support further research and design improvements for future trials.

Additionally, the safety profile of TLG-001 demonstrated no serious adverse events leading to discontinuation. Moving forward, Tsubota Lab plans to conduct additional trials in China, targeting regions where childhood myopia rates exceed 50%. The company aims to address the growing issue of myopia through innovative solutions, leveraging partnerships with local developers to maximize product value globally.

Further updates on the development schedule will be disclosed promptly as needed.